Rotigotine is a dopamine agonist used for Parkinson's disease and restless leg syndrome (RLS) which is available only as a slow-release transdermal patch applied to the skin. Rotigotine is also sold under the brand name Neupro. Rotigotine is in the same class of drugs as ropinirole and pramipexole.
Theory[edit | edit source]
Evidence[edit | edit source]
No clinicial trials have yet been carried out of rotigotine for patients with ME/CFS.
A single study of rotigotine for fibromyalgia had high dropout rates for both the drug and placebo, but did not appear to show a significant improvement in pain or other fibromyalgia symptoms at doses of 4mg or 8mg.
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Notable studies[edit | edit source]
- 2007, The use of rotigotine for treatment of reducing signs and symptoms of fibromyalgia in adults. Summary (not peer reviewed)
See also[edit | edit source]
Learn more[edit | edit source]
- Rotigotine - drugs.com
- Rotigotine transdermal - drugs.com
- Rotigotine - MedlinePlus
- Rotigotine - DrugBank Online
References[edit | edit source]
- "Rotigotine: Indications, Side Effects, Warnings". Drugs.com. Retrieved February 21, 2022.
- "Rotigotine Transdermal Advanced Patient Information". Drugs.com. Retrieved February 21, 2022.
- "Pramipexole: MedlinePlus Drug Information". medlineplus.gov. Retrieved February 21, 2022.
agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.